Bharat Parenterals Approves ₹300 Crore Biologics CDMO Facility Expansion

Varenyam Bio expanded its Savli facility to add biologics and biosimilar CDMO capability alongside oncology, targeting US, EU and SRA markets. Phase 1 capex doubled to ₹300 crore from ₹150 crore, with completion targeted for Q2 2028. Context: timeline extends beyond the earlier September 2027 target.